Apyx medical corporation receives fda 510(k) clearance for the use of renuvion® for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq:apyx) (the “company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as renuvion®, today announced it has received 510(k) clearance from the u.s. food and drug administration (“fda”) for the use of the renuvion apr handpiece “for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.” “we are pleased to receive 510(k) clearance for the use.
APYX Ratings Summary
APYX Quant Ranking